Aggressive surgery for advanced ovarian cancer performed by a multidisciplinary team: A retrospective analysis on a large series of patients.
Journal
Surgery open science
ISSN: 2589-8450
Titre abrégé: Surg Open Sci
Pays: United States
ID NLM: 101768812
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
18
12
2018
revised:
09
05
2019
accepted:
09
05
2019
entrez:
6
8
2020
pubmed:
30
6
2019
medline:
30
6
2019
Statut:
epublish
Résumé
To evaluate the impact of extended surgical treatment performed by a team of gynecologists and general surgeons on postoperative morbidity and survival of patients with advanced ovarian cancer. We collected data of 156 patients with advanced ovarian cancer stage IIb-III-IV according to International Federation of Gynecology and Obstetrics classification and treated with primary cytoreduction. End points were perioperative and postoperative complications and cancer-related survival. In 51 cases (51/156, 32.7%) a multivisceral resection was completed. Postoperative complications occurred in 52 cases (33.3%). The duration of the surgical procedure as well as the need for diaphragmatic peritonectomy were the factors independently associated with the development of postoperative complications. Five-year cancer-related survival rate was of 50.7%: only histotype and residual tumor resulted significantly associated. Our results highlight the importance of a team of gynecologists and general surgeons with specific interests and skills to achieve cytoreduction as rapidly as possible, even when it implies very complex maneuvers.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the impact of extended surgical treatment performed by a team of gynecologists and general surgeons on postoperative morbidity and survival of patients with advanced ovarian cancer.
METHODS
METHODS
We collected data of 156 patients with advanced ovarian cancer stage IIb-III-IV according to International Federation of Gynecology and Obstetrics classification and treated with primary cytoreduction. End points were perioperative and postoperative complications and cancer-related survival.
RESULTS
RESULTS
In 51 cases (51/156, 32.7%) a multivisceral resection was completed. Postoperative complications occurred in 52 cases (33.3%). The duration of the surgical procedure as well as the need for diaphragmatic peritonectomy were the factors independently associated with the development of postoperative complications. Five-year cancer-related survival rate was of 50.7%: only histotype and residual tumor resulted significantly associated.
CONCLUSIONS
CONCLUSIONS
Our results highlight the importance of a team of gynecologists and general surgeons with specific interests and skills to achieve cytoreduction as rapidly as possible, even when it implies very complex maneuvers.
Identifiants
pubmed: 32754692
doi: 10.1016/j.sopen.2019.05.005
pii: S2589-8450(19)30012-0
pmc: PMC7391894
doi:
Types de publication
Journal Article
Langues
eng
Pagination
43-47Informations de copyright
© 2019 The Authors.
Références
J Clin Oncol. 2002 Mar 1;20(5):1248-59
pubmed: 11870167
Ann Surg Oncol. 2010 Jun;17(6):1642-8
pubmed: 20165986
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Br J Obstet Gynaecol. 1989 Aug;96(8):889-92
pubmed: 2775686
Int J Gynecol Cancer. 2004 Sep-Oct;14(5):772-8
pubmed: 15361183
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
Gynecol Oncol. 2018 May;149(2):263-269
pubmed: 29550182
Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1014-22
pubmed: 16343177
Obstet Gynecol. 1999 Jan;93(1):21-4
pubmed: 9916949
Surg Endosc. 2018 Apr;32(4):2026-2037
pubmed: 29052073
Gynecol Oncol. 2009 Jul;114(1):26-31
pubmed: 19395008
N Engl J Med. 2010 Sep 2;363(10):943-53
pubmed: 20818904
Gynecol Oncol. 2016 Jan;140(1):42-7
pubmed: 26556769
Am J Obstet Gynecol. 2007 Dec;197(6):676.e1-7
pubmed: 18060979
Gynecol Oncol. 2016 Feb;140(2):215-20
pubmed: 26691222
Ann Surg Oncol. 2017 Nov;24(12):3692-3699
pubmed: 28871563
Obstet Gynecol. 2009 Apr;113(4):775-82
pubmed: 19305319
Am J Obstet Gynecol. 2008 Dec;199(6):642.e1-6
pubmed: 18801470
Gynecol Oncol. 2015 Aug;138(2):246-51
pubmed: 26037900
Obstet Gynecol. 2006 Jan;107(1):77-85
pubmed: 16394043
Gynecol Oncol. 2018 Sep;150(3):446-450
pubmed: 30001834
Gynecol Oncol. 2017 Oct;147(1):73-80
pubmed: 28800941
J Gynecol Oncol. 2015 Oct;26(4):336-42
pubmed: 26197773